Skip to main content
Sartorius AG logo

Sartorius AG — Investor Relations & Filings

Ticker · SRT3 ISIN · DE0007165607 LEI · 529900EQV2DY4FOAMU38 F Manufacturing
Open in API
Filings indexed 392 across all filing types
Latest filing 2026-05-21 Regulatory Filings
Country DE Germany
Listing F SRT3

About Sartorius AG

https://www.sartorius.com/en

Sartorius is a leading international partner for the biopharmaceutical industry and life science research. The company provides a comprehensive portfolio of products and services that support the entire drug development and manufacturing process, from initial discovery to production. Key offerings include advanced solutions for filtration, fermentation, fluid management, cell analysis, and process analytics. The laboratory products division supplies essential equipment such as balances, pipettes, and water purification systems. Sartorius focuses on simplifying complex scientific processes to help customers translate discoveries into effective medicines more quickly and efficiently.

Recent filings

Filing Released Lang Actions
Sartorius opens new competence center for cell and gene therapy components in Freiburg, Germany
Regulatory Filings Classification · 65% confidence The document is a corporate press release announcing the opening of a new competence center in Freiburg. It contains no financial results, no regulatory form, no voting or dividend details, no M&A or share transaction information, and is not a formal report but rather a news announcement. It therefore falls into the miscellaneous regulatory/corporate news category.
2026-05-21 English
Sartorius completes placement of bond with a volume of 500 million euros
Regulatory Filings
2026-05-06 English
SARTORIUS AG: Dr. Alexandra Gatzemeyer, Acquisition of 5,203 ordinary shares as a sharebased compensation component upon fulfillment of the relevant contractual condition.
Director's Dealing
2026-05-06 English
Q1 statement / Q1 financial report 2026
Earnings Release Classification · 95% confidence The document is titled “Earnings Release” and presents Sartorius’s first-quarter 2026 financial highlights, including summary bullet points (sales growth, EBITDA margin, guidance confirmation), narrative discussion of quarterly performance, and key performance indicator tables. It is a standalone press release announcing quarterly results, matching the definition of an Earnings Release. There is no indication of a full interim report, management discussion & analysis with extensive disclosures, or only an announcement of report publication. Therefore, it should be classified as an Earnings Release (ER). Q1 2026
2026-04-28 English
Sartorius AG Supervisory Board extends appointment of board member Florian Funck
Board/Management Information Classification · 90% confidence The document is a corporate announcement detailing an extension of appointment for an Executive Board member (CFO) by the Supervisory Board of Sartorius AG. It is a personnel/management change notice rather than financial results, a full annual report, or other regulatory filing. Therefore, it falls under Board/Management Information (MANG).
2026-04-24 English
Sartorius marks positive start to 2026: Considerable sales revenue growth and resilient profit margin
Earnings Release Classification · 90% confidence The document is a press release issued on April 23, 2026 announcing Sartorius AG’s first-quarter 2026 financial results, key metrics (sales revenue, EBITDA, guidance), and inviting investors to a conference call. It is not a comprehensive quarterly report (IR) but rather the initial earnings announcement summarizing quarterly performance and guidance. Therefore, it is classified as an Earnings Release (ER). Q1 2026
2026-04-23 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.